Ofloxacin is a quinolone antimicrobial sold in the U.S. under 6 brand and generic names, for bronchitis, chlamydia infections and bacterial conjunctivitis. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Ocuflox (application NDA019921). Other ofloxacin products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
The recommended dosage regimen for the treatment of bacterial conjunctivitis is: Days 1 and 2 Instill one to two drops every two to four hours in the affected eye(s). Days 3 through 7 Instill one to two drops four times daily. The recommended dosage regimen for the treatment of bacterial corneal ulcer is: Days 1 and 2 Instill one to two drops into the affected eye every 30 minutes, while awake. Awaken at approximately four and six hours after retiring and instill one to two drops. Days 3 through 7 to 9 Instill one to two drops hourly, while awake. Days 7 to 9 through treatment completion Instill one to two drops, four times daily.
Ophthalmic Use The most frequently reported drug-related adverse reaction was transient ocular burning or discomfort. Other reported reactions include stinging, redness, itching, chemical conjunctivitis/keratitis, ocular/periocular/facial edema, foreign body sensation, photophobia, blurred vision, tearing, dryness, and eye pain. Rare reports of dizziness and nausea have been received. Refer to Warnings for additional adverse reactions.
OCUFLOX ® solution is contraindicated in patients with a history of hypersensitivity to ofloxacin, to other quinolones, or to any of the components in this medication ( s ee Warnings ) .
Specific drug interaction studies have not been conducted with OCUFLOX ® ophthalmic solution. However, the systemic administration of some quinolones has been shown to elevate plasma concentrations of theophylline, interfere with the metabolism of caffeine, and enhance the effects of the oral anticoagulant warfarin and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving cyclosporine concomitantly.
Dairy, calcium, iron & antacids
Separate the antibiotic from dairy, supplements, and antacids by a couple of hours — take it at the interval the label or your pharmacist specifies.
Tetracycline — MedlinePlus (U.S. National Library of Medicine) ↗Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 70/100 | Prescription | Drops | Generic | $1 | View → | |
| 2 | 64/100 | Prescription | Solution | Generic |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| RDY;280 | 500 mg | orange | capsule | — |
| RDY;281 | 750 mg | yellow | capsule | — |
| ZC55 | 250 mg | white | capsule | — |
| I;18 | 750 mg | white | capsule | — |
| I;26 | 500 mg | orange | capsule | — |
| L54 | 500 mg |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension Rx Only
Temperature Abuse
Sandoz Inc · Aug 13, 2025
Ciprofloxacin Ophthalmic Solution USP
Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
FDC Limited · Mar 11, 2025
CIPROFLOXACIN OPHTH SOLUTION
Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
Direct Rx · Jan 31, 2025
Ciprofloxacin Ophthalmic Solution USP
Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle
FDC Limited · Dec 16, 2024
Ciprofloxacin ophthalmic solution USP
Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.
FDC Limited · Jul 23, 2024
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
| $1 |
| View → |
| 3 | Not yet rated | Prescription | Tablet | Generic | $1 | View → |
| 4 | Not yet rated | Prescription | Injectable | Generic | $1 | View → |
| 5 | Not yet rated | Prescription | Injectable | Generic | $1 | View → |
| 6 | Not yet rated | Prescription | Drops | Generic | $1 | View → |
| white |
| capsule |
| — |
| Y102 | 500 mg | white | oval | — |
|---|
| C213 | 200 mg | yellow | oval | — |
|---|
| C212 | 300 mg | white | oval | — |
|---|
| C211 | 400 mg | yellow | oval | — |
|---|
| E451 | 500 mg | white | oval | — |
|---|
| L54 | 500 mg | white | capsule | — |
|---|